[{"address1": "321 Summer Street", "address2": "Suite 400", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857 330 4340", "website": "https://www.inozyme.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 67, "companyOfficers": [{"maxAge": 1, "name": "Dr. Douglas A. Treco Ph.D.", "age": 66, "title": "CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 552017, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Axel  Bolte M.B.A., M.Sc.", "age": 52, "title": "Co-Founder, Senior Advisor & Director", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 40893, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sanjay S. Subramanian M.B.A., M.S.", "age": 48, "title": "CFO, Head of Business Development, Principal Accounting Officer & Corporate Secretary", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 607383, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew  Winton Ph.D.", "age": 46, "title": "Senior VP & COO", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 602100, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Demetrios  Braddock M.D., Ph.D.", "title": "Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yves  Sabbagh Ph.D.", "title": "Senior VP, Chief Scientific Officer & Chair of the Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stefan  Riley", "title": "Director of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gayle  Gironda", "title": "Senior VP & Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Di Palma M.B.A.", "age": 65, "title": "Consultant", "yearBorn": 1959, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Petra  Duda M.D., Ph.D.", "title": "Chief Medical Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.0, "open": 4.0, "dayLow": 4.0, "dayHigh": 4.0, "regularMarketPreviousClose": 4.0, "regularMarketOpen": 4.0, "regularMarketDayLow": 4.0, "regularMarketDayHigh": 4.0, "payoutRatio": 0.0, "beta": 2.293, "forwardPE": -3.6866357, "volume": 1320482, "regularMarketVolume": 1320482, "averageVolume": 2546837, "averageVolume10days": 1174076, "averageDailyVolume10Day": 1174076, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 258247200, "fiftyTwoWeekLow": 0.721, "fiftyTwoWeekHigh": 6.24, "fiftyDayAverage": 3.093974, "twoHundredDayAverage": 2.6322865, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 220425296, "profitMargins": 0.0, "floatShares": 29983802, "sharesOutstanding": 64561800, "sharesShort": 3384905, "sharesShortPriorMonth": 3836528, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.052399997, "heldPercentInsiders": 0.01263, "heldPercentInstitutions": 0.94287, "shortRatio": 0.78, "shortPercentOfFloat": 0.056700002, "impliedSharesOutstanding": 64561800, "bookValue": 0.493, "priceToBook": 8.11359, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -106716000, "trailingEps": -1.68, "forwardEps": -1.62, "enterpriseToEbitda": -2.105, "52WeekChange": -0.30313587, "SandP52WeekChange": 0.20277917, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "INZY", "underlyingSymbol": "INZY", "shortName": "Inozyme Pharma, Inc.", "longName": "Inozyme Pharma, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f627b06e-ce15-3126-896c-1db8a4222086", "messageBoardId": "finmb_568596329", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.0, "targetHighPrice": 4.0, "targetLowPrice": 4.0, "targetMeanPrice": 4.0, "targetMedianPrice": 4.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 4, "totalCash": 84776000, "totalCashPerShare": 1.313, "ebitda": -104737000, "totalDebt": 46954000, "quickRatio": 1.982, "currentRatio": 2.189, "debtToEquity": 147.663, "returnOnAssets": -0.48452, "returnOnEquity": -1.4168899, "freeCashflow": -56378000, "operatingCashflow": -96523000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-08-02"}]